Spinout Spotlight — Scipher Medicine

Nov 14, 2022 | Innovation, Spinout

About $552 billion is wasted annually when patients are prescribed drugs they don’t respond to.

To solve this waste problem, Scipher Medicine’s first-in-class precision medicine platform uses a patient’s individual molecular data to determine which drug will work best for each patient—ensuring that the optimal therapy is prescribed.

The platform ensures that optimal treatment is prescribed from day one by utilizing the patient’s fundamental disease biology and molecular signature tests to inform treatment—improving lives and saving money. This approach eliminates error from current disease treatment, that is typically based solely on symptoms and classification—and is often negatively influenced by medical bias.

Albert László Barabási

Photo by Adam Glanzman/Northeastern University

Scipher co-founders Dr. Joe Loscalzo and Dr. Albert-László Barabási pioneered the Human Interactome—the map of human biology that explains how proteins expressed from genes interact to cause specific disease phenotypes. The Human Interactome provides the wiring diagram needed to interpret dynamic molecular data from patients. This interpretation is used to determine an individual’s unique disease biology, enabling the Scipher platform’s success.

Northeastern’s Center for Research Innovation (CRI) negotiated and executed a license agreement for Scipher’s intellectual property, allowing the company to raise several rounds of funding totaling over $200M. The license also enabled them to secure several grants from organizations such as the NIH, DARPA, ONR, related to the patents that were licensed.

Scipher has since partnered with several biopharmaceutical companies and their platform has been applied to find effective pre-clinical treatments for difficult-to-treat ailments such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), COVID-19, and various autoimmune diseases.

In February 2022, the company raised $110 million of Series D venture funding in a deal led by Cowen Healthcare Investments, putting the company’s pre-money valuation at $380 million.

Learn more about Scipher Medicine here.

Written by Elizabeth Creason